Morgan Stanley Maintains Underweight on Y-mAbs Therapeutics, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz maintains an Underweight rating on Y-mAbs Therapeutics (NASDAQ:YMAB) and lowers the price target from $12 to $11.
August 13, 2024 | 12:53 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley analyst Michael Ulz maintains an Underweight rating on Y-mAbs Therapeutics and lowers the price target from $12 to $11.
The Underweight rating and lowered price target from a major financial institution like Morgan Stanley is likely to negatively impact investor sentiment and the stock price of Y-mAbs Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100